AC over-expression has been documented in many cancers exhibiting or prone to develop drug-resistance—including melanoma, prostate cancer and glioblastoma—and several AC inhibitors have been developed with the aim of reducing drug resistance [11,12,13]. Here, ASAH1 is linked to glioblastoma.